China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its subsidiary Chia Tai Tianqing and Ping An-Shionogi Co., Ltd, a joint venture between China-based commercial insurance firm Ping An Insurance (Group) Ltd and Japanese pharmaceutical firm Shionogi & Co., Ltd. Under this initially 11-year accord, Chia Tai Tianqing will be responsible for the exclusive promotion of naldemedine, a therapy for opioid-induced constipation (OIC), in mainland China. Financial details of the agreement have not been disclosed.
Naldemedine: A Peripheral μ-Opioid Receptor Antagonist
Naldemedine, developed by Shionogi, is a peripheral μ-opioid receptor antagonist that has been registered in the US, European Union, Japan, Taiwan, and Hong Kong. The drug was introduced in Bo’ao Lecheng in 2022 as a clinically urgent medication, highlighting its importance in addressing the needs of patients suffering from OIC.
Expanding Access to Naldemedine in China
The partnership between Chia Tai Tianqing and Ping An-Shionogi aims to expand access to naldemedine for patients in mainland China, providing a much-needed treatment option for those dealing with the effects of opioid-induced constipation. This agreement underscores the commitment of both companies to improving patient outcomes and enhancing the availability of innovative therapies in the Chinese market.-Fineline Info & Tech
